Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
NeoGenomics, Inc. NEO
$19.10
-$0.7 (-3.68%)
На 18:00, 12 мая 2023
+23.93%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
2498802450.00000000
-
week52high
20.54
-
week52low
6.00
-
Revenue
509728000
-
P/E TTM
-13
-
Beta
1.12318300
-
EPS
-1.12000000
-
Last Dividend
0.40000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Hold | Buy | 22 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 18 авг 2022 г. |
| Needham | Buy | Buy | 10 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 10 авг 2022 г. |
| Goldman Sachs | Buy | Buy | 10 авг 2022 г. |
| Benchmark | Hold | Buy | 26 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 14 ноя 2022 г. |
| Raymond James | Outperform | Outperform | 11 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 09 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 09 ноя 2022 г. |
| Needham | Buy | Hold | 01 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Harris Melody | A | 201613 | 201613 | 01 янв 2023 г. |
| Harris Melody | A | 108225 | 108225 | 01 янв 2023 г. |
| Sikri Vishal | A | 148680 | 225 | 31 дек 2022 г. |
| Dieter Cynthia J | D | 30762 | 959 | 31 дек 2022 г. |
| Sherman Jeffrey Scott | A | 249169 | 249169 | 05 дек 2022 г. |
| Sherman Jeffrey Scott | A | 133809 | 89206 | 05 дек 2022 г. |
| Sherman Jeffrey Scott | A | 44603 | 44603 | 05 дек 2022 г. |
| Stone Warren | A | 166113 | 166113 | 01 дек 2022 г. |
| Stone Warren | A | 89206 | 89206 | 01 дек 2022 г. |
| Perez David Brian | A | 10300 | 10300 | 03 ноя 2022 г. |
Новостная лента
NeoGenomics, Inc. (NEO) Q1 2023 Earnings Call Transcript
Seeking Alpha
08 мая 2023 г. в 20:57
NeoGenomics, Inc. (NASDAQ:NEO ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - CEO Jeff Sherman - CFO Warren Stone - President of Clinical Service Division Vishal Sikri - President of Advanced Diagnostics Division Melody Harris - President of Enterprise Operations Conference Call Participants Puneet Souda - SVB Securities David Westenberg - Piper Sandler Dan Brennan - TD Cowen Andrew Brackmann - William Blair David Delahunt - Goldman Sachs Tejas Savant - Morgan Stanley Andrew Cooper - Raymond James Derik De Bruin - Bank of America Merrill Lynch Mark Massaro - BTIG Jacob Krahenbuhl - Stephens Operator Welcome to the NeoGenomics First Quarter 2023 Financial Results Conference Call and Webcast. At this time all participants are in listen only mode.
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 19:45
NeoGenomics (NEO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.20 per share a year ago.
3 Top Stocks Likely to Exceed Estimates This Earnings Season
Zacks Investment Research
28 апр 2023 г. в 08:23
These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Portillo's Inc. (PTLO), NeoGenomics (NEO) and Wingstop (WING).
NeoGenomics to Announce First Quarter 2023 Financial Results
Accesswire
17 апр 2023 г. в 07:00
FT. MYERS, FL / ACCESSWIRE / April 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it will release its first quarter 2023 financial results on Monday, May 8, 2023. Along with the release, NeoGenomics will host a webcast and conference call that day at 4:30 p.m.
5 Top Stocks Likely to Come Up With Earnings Beat
Zacks Investment Research
13 апр 2023 г. в 09:08
These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).